5.1824
Cytek Biosciences Inc stock is traded at $5.1824, with a volume of 139.43K.
It is down -0.38% in the last 24 hours and up +1.57% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$5.20
Open:
$5.25
24h Volume:
139.43K
Relative Volume:
0.11
Market Cap:
$662.34M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-57.58
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
-2.45%
1M Performance:
+1.57%
6M Performance:
+40.38%
1Y Performance:
-9.60%
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CTKB
Cytek Biosciences Inc
|
5.18 | 664.90M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
107.42 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.36 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.74 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.35 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.83 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Aug Closing: Is Cytek Biosciences Inc stock overvalued or fairly priced2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Institutional owners may take dramatic actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 6.9% drop adds to one-year losses - simplywall.st
Why Cytek Biosciences Inc. (8EQ) stock attracts HNW investorsJuly 2025 Big Picture & High Conviction Investment Ideas - bollywoodhelpline.com
CYTEK BIOSCIENCES Q4 2025 Earnings Preview: Recent $CTKB Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.2%Here's What Happened - MarketBeat
Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 - marketscreener.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Rating of “Hold” from Analysts - Defense World
Cytek Biosciences Preliminary Q4 Revenue Up 8% - Nasdaq
Cytek Biosciences Reports Preliminary Revenue of Approximately $201 Million for Full Year 2025 - Quiver Quantitative
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results - GlobeNewswire
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Rating of "Hold" from Analysts - MarketBeat
Will Cytek Biosciences Inc. (8EQ) stock top growth indexesWeekly Profit Report & High Accuracy Trade Signal Alerts - ulpravda.ru
Why Cytek Biosciences Inc. stock is a must watch in 20252025 Pullback Review & Community Consensus Trade Signals - Улправда
Is Cytek Biosciences Inc. stock attractive for retirement portfoliosRisk Management & Technical Confirmation Trade Alerts - Улправда
What analyst consensus implies for Cytek Biosciences Inc. (8EQ) stockBond Market & Weekly High Return Forecasts - Улправда
CTKB FinancialsIncome Statement - Quiver Quantitative
Cytek Biosciences (NASDAQ:CTKB) Given New $5.00 Price Target at TD Cowen - MarketBeat
User | bentoncourier.comCytek Biosciences, Inc.Common Stock (Nasdaq:CTKB) Stock Quote - FinancialContent
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt In A Risky Way? - Futubull
2026 world cup standings odds: How currency fluctuations impact Cytek Biosciences Inc. stock2026 world cup usa national team round of 16 playmakers transition play match prediction analysis - Улправда
Cytek Biosciences Inc 8EQ Stock Analysis and ForecastCandlestick Pattern Analysis & Affordable Portfolio Strategies - earlytimes.in
What risks investors should watch in Cytek Biosciences Inc stockGap Down & Free Safe Capital Growth Stock Tips - Bộ Nội Vụ
How currency fluctuations impact Cytek Biosciences Inc. stockStock Screening Results & Big Data Market Reports - bollywoodhelpline.com
What dividend safety score for Cytek Biosciences Inc. stockLong-Term Investment Plans & Fast Profit Trading Strategies - bollywoodhelpline.com
Cytek Biosciences webinar explores lung cell communication advances - Traders Union
Cytek Biosciences Data Breach Investigation - Claim Depot
Cytek Biosciences Data Breach Exposes Social Security Numbers - Claim Depot
Book value per share of Cytek Biosciences, Inc. – DUS:8EQ - TradingView — Track All Markets
How Cytek Biosciences Inc. stock responds to policy changes2025 Trading Volume Trends & Accurate Buy Signal Alerts - Улправда
Pharma News: How Cytek Biosciences Inc. stock responds to policy changesJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - Улправда
Is Cytek Biosciences Inc. (8EQ) stock a buy on weakness2025 EndofYear Setup & Safe Capital Preservation Plans - DonanımHaber
Is Cytek Biosciences Inc. (8EQ) stock at risk of policy regulationTrade Ideas & High Accuracy Trade Signal Alerts - DonanımHaber
Cytek Biosciences Earnings Notes - Trefis
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Cytek BioSciences Inc (CTKB) expanding its growth trajectory ahead - Setenews
Why Cytek Biosciences Inc. (8EQ) stock stays on buy listsQuarterly Portfolio Report & High Accuracy Buy Signal Tips - Newser
Institutional Owners May Consider Drastic Measures as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Recent US$58m Drop Adds to Long-term Losses - 富途牛牛
Brown Capital Management LLC Has $24.17 Million Stock Position in Cytek Biosciences, Inc. $CTKB - MarketBeat
Is Cytek Biosciences Inc. stock overvalued by current metricsJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - Newser
Can Cytek Biosciences Inc. stock beat market expectations this quarter - Newser
Can Cytek Biosciences Inc. (8EQ) stock sustain revenue momentumGDP Growth & Safe Capital Growth Plans - Newser
Why Cytek Biosciences Inc. stock attracts global investorsWeekly Trend Report & Fast Gain Stock Tips - Newser
Can Cytek Biosciences Inc. stock maintain operating marginsEarnings Growth Summary & Entry Point Strategy Guides - Newser
Is Cytek Biosciences Inc. (8EQ) stock attractive for dividend growthJuly 2025 Sentiment & Community Verified Trade Alerts - Newser
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytek Biosciences Inc Stock (CTKB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCombe William D. | Chief Financial Officer |
Jun 02 '25 |
Buy |
2.78 |
35,000 |
97,300 |
55,746 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):